CONFERENCE PROGRAM
The 23rd KSEA
Northeast Regional
Conference (NRC)
2014 KASBP
Spring Symposium
June 6-7, 2014
Sheraton Edison Hotel-Raritan Center
125 Raritan Center Parkway, Edison, NJ 08837 USA
Hosted by
Korean–American Scientists and Engineers Association
New Jersey, New York Metro Chapters and
KASBP
Sponsored by
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Welcome to 23rd NRC & 2014 KASBP Spring Symposium
The Korean-American Scientists and Engineers Association (KSEA) NJ, NY Metro Chapters, and KASBP will hold
the 23rd KSEA Northeast Regional Conference (2014 NRC) and 2014 KASBP Spring Symposium at Sheraton
Edison Hotel-Raritan Center, NJ, USA on June 6-7, 2014. The objective of this conference is to provide a forum
in which scientists and engineers in major areas present their research findings and share ideas. The 23rd KSEA
Northeast Regional Conference (2014 NRC) and 2014 KASBP Spring Symposium will also contribute greatly to
the advancement of research and development in both USA and Korea. In addition, it will provide an
opportunity for members and other subject matter experts to establish professional networks, as well as to
explore career opportunities.
The 23rd KSEA Northeast Regional Conference (2014 NRC) and 2014 KASBP Spring Symposium Committee
would like to extend an invitation to you to this wonderful forum and would appreciate if you would accept
this invitation. We are looking forward to seeing you all at the 23rd KSEA Northeast Regional Conference (2014
NRC) and 2014 KASBP Spring Symposium.
Yun H. CHOE, Ph.D.
K. Stephen SUH, Ph.D.
Jae-Hun KIM Ph.D.
KSEA-NJ
KSEA-NY Metro
KASBP
Conference Co-chair
Conference Co-chair
Conference Co-chair
1|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
2014 KASBP 봄 심포지엄 환영사
유한양행과 한미약품을 비롯하여 여러 유관 단체의 협조와 후원으로 치루어지는 2014 KASBP 봄 심포지엄에
참가하시는 여러분 모두를 진심으로 환영합니다. 이번 행사는 한국과 미국의 제약 및 관련 산업체에 종사하는
전문가들과 학교와 다양한 정부 출연 연구기관에서 근무하는 과학자들이 한 자리에 모여신규 의약품 발굴의
다양한 분야에서의 기초연구와 이후 신약개발 및 허가 과정에 걸친 동향과 사례들을 함께 공유할 수 있는 훌륭한
기회가 되리라 확신합니다. 아울러 이번 심포지엄에서는 미국의 대학과 다양한 연구기관에서 신약개발과
직간접적으로 연관된 연구에 우수한 성과를 내고 있는 젊은 과학자들을 발굴하여 장학금을 시상하여 이들을
격려하는 자리도 마련하며, 또한 제약관련 현장에서 연구하는 전문가들과 학교에서 박사과정과 박사후 연구원
과정에 있는 젊은 과학자들간의 토론자리를 마련하여 진로 모색과 산업현장에서의 연구동향을 서로 공유하는
자리도 포함되어있습니다.
여러분들의 성원과 관심속에 이번 행사가 풍성한 결실을 맺게 되기를 기대해봅니다. 앞으로도 저희 재미 한인
제약인 협회는 한국과 미국에서 활동하는 제약관련 전문가들 간의 유익한 정보교류와 네트워킹, 그리고 유용한
프로그램을 지속적으로 발전시키는데 최선을 다할 것을 약속 드립니다.
김재훈
KASBP 회장
2|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Congratulatory Message from the KSEA President
On behalf of the Korean-American Scientists and Engineers Association (KSEA), I
would like to welcome every one of you to the 23rd Northeast Regional Conference
(NRC) and KASBP Symposium 2014 and thank you for making this event a continued
success.
I myself being a NY Metro chapter member, this conference is very dear to me
because in its early days I served as the NRC program and conference chair in 1991-2.
In 1990s, four chapters, NY Metro, NJ, Philadelphia, and Lehigh Valley actively
participated. Back then, IT area was very strong due to the presence of the Bell
Laboratories, IBM and a good number of academia in the region. Recently, it seems a natural evolution for
NRC to join the KASBP representing the strength of the pharmaceutical industry in NJ. It is very commendable
that the KASBP requires all its members to become KSEA members, indeed an exemplary KSEA APS.
While the KSEA organizes a variety of conferences, the regional conferences like NRC/KASBP joint conference
uniquely place themselves, taking the best of the locality and the regional technical strength. I am proud that
the NRC/KASBP2014 is doing exactly that. The merit of this multidisciplinary conference is that potential
future breakthroughs will germinate from the boundaries of various technical disciplines; we must explore the
hidden treasures at these boundaries. This harmonization effort calls for open minds and collaborative spirits
of people. I believe this joint conference will help revitalize activities and solidarity of NJ, NY Metro Chapters
and KASBP and become the flagship region of the KSEA.
I believe your experience with the KASBP/NRC joint conference will be an exciting one, whether it is learning
opportunities, discovering new ideas, cultivating research and development collaborations, or appreciating
rare networking opportunities to make new friends or renew bonds with old colleagues.
Lastly, I would like to thank the conference co-chairs Dr. Jaehoon Kim, Dr. Yun Chae, and Dr. Stephen Suh and
all other organizing committee members, advisors, invited speakers, session chairs, volunteers for their
dedication for this great conference. Thanks also go to Dr. Kyeongho Yang and Dr. Bongjun Ko for their effort
in revitalizing IT group. I appreciate very much for sponsors of their generous support making this event
possible.
All the Best!
Thank you.
Myung Jong Lee
42nd KSEA President
3|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
23rd NRC & 2014 KASBP Spring Symposium Organizing Committee
Yun H. Choe (KSEA-NJ)
Conference
Co-Chairs
Conference
Advisors
Program Chairs
Fund raising
Chairs
Publication
Coordinator
Local
arrangement
Coordinators
Treasurers
Registration
Coordinators
Hak M. Lee (KASBP)
Sung Soo Kim (KSEA-NY)
Lucas & Mercanti, LLP, ychoe@lmiplaw.com
Hackensack University Medical Center ,
KSuh@HackensackUMC.org
IFF, jkim7813@gmail.com
Dialogic Inc., khyang0@yahoo.com
PTC Therapeutics, ymoon@ptcbio.com
IBM, kangwook.lee.ibm@gmail.com
VaxInnate, Youngsun.Kim@vaxinnate.com
PTC Therapeutics, csleesammy@yahoo.com
AT&T, slee@research.att.com
IBM, Bongjun_ko@us.ibm.com
New York University, sparknate@gmail.com
Rutgers University, dhyou21@gmail.com
RevHealth, LLC, kimsahee@gmail.com
Lucas & Mercanti, LLP, ychoe@lmiplaw.com
IFF, jkim7813@gmail.com
Hackensack University Medical Center ,
KSuh@HackensackUMC.org
Celgene, emhur315@gmail.com
Lucas & Mercanti, ychoe@Lmiplaw.com
Alcatel-Lucent, jaeyoung.kwak@alcatel-lucent.com
Hackensack University Medical Center,
KSuh@HackensackUMC.org
Lucas & Mercanti, ychoe@Lmiplaw.com
AT&T, Yjkim@research.att.com
PTC Therapeutics, shwang@ptcbio.com
Alcatel-Lucent, young.jin_kim@alcatel-lucent.com
BMS, chris.d.lee@bms.com
Hackensack University Medical Center ,
KSuh@HackensackUMC.org
ACS (Applied Communication Sciences),
hee_chang_kim@yahoo.com
Shionogi USA, haklee60@yahoo.com
HRCAP, andrew@hrcap.com
KangWook Lee (KSEA-NY)
IBM, kangwook.lee.ibm@gmail.com
K Stephen Suh (KSEA-NY)
Jae-Hun Kim (KASBP)
Kyeong Ho Yang (KSEA-NJ)
Young-Choon Moon (KASBP)
KangWook Lee (KSEA-NY)
Youngsun Kim (KASBP) - BT
Chang-Sun Lee (KASBP) -BT
Seungjoon Lee (KSEA-NJ) - IT
Bongjun Ko (KSEA-NY) - IT
Sang Hoon Lee (KSEA-NJ)- ENG
Dahea Diana YOU (YG)
Sahee KIM (YG)
Yun H. Choe (KSEA-NJ)
Jae-Hun Kim (KASBP)
K. Stephen Suh (KSEA-NY)
Eun Mi Hur (KASBP)
Yun H. Choe (KSEA-NJ)
Jaeyoung Kwak (KSEA-NJ)
K Stephen Suh (KSEA-NY)
Yun H Choe (KASBP)
Yeon-Jun Kim (KSEA-NJ)
Seongwoo Hwang (KASBP)
Young Jin Kim (KSEA-NJ)
Chris D. Lee (KASBP)
K Stephen Suh (KSEA-NY)
Heechang Kim (KSEA-NJ)
Auditors
Bylaw
Committee
4|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
2013-2014 KSEA-NY Metro Officers
Title
Name
Affiliation
President
Grace Park
BD Science
President Designated
K. Stephen Suh
Hackensack Med Center
1st Vice President
K. Stephen Suh
Hackensack Med Center
2nd Vice President
Jeonghee Shin
IBM
Executive Director
Ju-hyun Lee
Nathan Kline Institute
Financial Director
Chang-Young Nam
Brookhaven Nat Lab
2013-2014 KSEA-NJ Officers
Title
President
1st Vice President
2nd Vice President
General (Media) Director
Finance Director
Membership Director-IT
Membership Director-BT
Technical Director-IT
Technical Director-BT
YG Co-Directors
Audit
Name
Yun H. Choe
Jae-young Kwak
Youngsun Kim
Jaewon Kang
Yeon-Jun Kim
Young Jin Kim
JunHyuk Heo
Seungjoon Lee
Cheol K. Chung
Diana Dahea You
Sahee Kim
Heechang Kim
Affiliation
Lucas & Mercanti, LLP
Alcatel-Lucent
VaxInnate
Telcordia
AT&T
Bell Laboratories
Merck
AT&T
Merck
Rutgers University
RevHealth, LLC
ACS (Applied
Communication Sciences
5|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
2013-2014 KASBP Officers
Title
Name
Affiliation
President
Jae-Hun Kim
IFF
President Designated
Youngsun Kim
VaxInnate
1st Vice President
Yun H. Choe
Lucas & Mercanti
2nd Vice President
Jae Uk Jung
GSK
Executive Director
Cheol K. Chung
Merck
General Director
Suktae Choi
Celgene
Science Director
Eunsung Junn
Rutgers University
Program Director
Chang-Sun Lee
PTC Therapeutics
Financial Director
Seongwoo Hwang
PTC Therapeutics
Web Director
Alex Kim
Merck
Diana Dahea You
Rutgers University
Sahee Kim
RevHealth, LLC
1st Membership Director
Chris Lee
Bristol-Myers Squibb
2nd Membership Director
Jun Hyuk Heo
Merck
Auditor
Hak-Myung Lee
Shionogi Inc.
Legal Director
Elizabeth Lee
Lucas & Mercanti
Boston Regional Director
Sean Kim
Novartis
Philadelphia Regional Director
Yong-Hwan Jin
GSK
Connecticut Regional Director
Ik-Hyeon Paik
Melinta
DC Regional Director
Luke Oh
Questcor Pharmaceuticals
Councilor
Hak-Myung Lee
Shionogi Inc.
Councilor
Young-Choon Moon
PTC Therapeutics
Councilor
Je-Phil Ryoo
NAL Pharmaceuticals
Advisor
Nakyen Choy
Dow AgroScience
Advisor
Moo Je Sung
Novartis
YG Co- Directors
6|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Program at Glance
Friday
KASBP
AM
PM
7-8
8-9
9-10
10-11
11-12
12-1
1-2
2-3
3-4
4-5
5-6
6-7
7-8
8-9
9-10
10-11
11-12
KSEA
Arrival
Hotel Self Check-In
BT (KASBP)
Round Table Session
Breakfast
Saturday
IT
Registration
Breakfast
AM Session / Coffee
Break
AM Session /
Coffee Break
YG
Registration
Breakfast
AM Session with
BT/IT/ENG
Lunch / Poster
PM Session / Coffee
Break
PM Session /
Coffee Break
PM Session /
Coffee Break
Registration
Banquet / Keynote Speech
Sponsor Presentation
Round Table
Session &
Networking
Round Table
Session &
Networking
Dinner: Ichiumi Restaurant
352 Menlo Park Dr (Menlo Park Mall), Edison, NJ 08837
Have A Safe Trip and See You Again…
7|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Program Summary
June 5, 2014, Thursday
06:00 PM
VIP dinner: KASBP staffs and Sponsors
June 6, 2014, Friday (ALL)
05:30 PM – 06:30 PM
Registration & Networking
06:30 PM – 07:40 PM
Opening & Congratulatory Remarks and Dinner
07:40 PM – 08:30 PM
Keynote Speech
08:30 PM – 09:00 PM
Sponsor Presentation
09:00 PM – 11:00 PM
BT: Round Table Discussion A (Pharma industry –Academia, and Career Development)
IT: Round Table Session & Networking
YG: Join BT or IT
June 7, 2014, Saturday (BIO&PHAMA SCIENCE)
07:00 AM – 08:30 AM
Round Table Discussion B (Regulatory Perspectives in Drug Approval Process)
08:30 AM – 09:00 AM
Registration & Light Breakfast
09:00 AM – 09:15 AM
Opening Remarks
09:15 AM – 10:25 AM
Forum A1 Presentation
10:25 AM – 10:45 AM
Coffee Break
10:45 AM – 11:55 AM
Forum A2 Presentation
11:55 AM – 12:10 PM
Fellowship Award Ceremony
12:10 PM – 02:30 PM
Lunch & Poster Presentation
02:30 PM – 03:55 PM
Special Lecture and Forum B1 Presentation
03:55 PM – 04:15 PM
Coffee Break
04:15 PM – 05:05 PM
Sponsor Talk and Forum B2 Presentation
05:05 PM – 05:15 PM
Closing Remarks
06:00 PM – 09:00 PM
Dinner
June 7, 2014, Saturday (IT)
09:00 AM – 10:30 AM
Information Technology I: Software Defined Networking
10:30 AM – 11:00 AM
Coffee Break
11:00 AM – 12:30 AM
Information Technology II: Big Data
12:30 PM– 01:30 PM
Networking Lunch
01:30 PM – 03:30 PM
Information Technology III: Cloud Computing and Virtualization
03:30 PM – 04:00 PM
Coffee Break
04:00 PM – 05:00 PM
Information Technology IV: Open Discussion – What’s Next?
05:00 PM – 05:15 PM
Closing Remarks
06:00 PM – 09:00 PM
Dinner
8|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
June 7, 2014, Saturday (YG)
07:00 AM – 12:00 PM
Breakfast, Registration, BT and IT session
12:00 PM – 02:20 PM
Networking Lunch / Poster Session
02:20 PM – 03:30 PM
Young Generation Session I
03:30 PM – 03:50 PM
Coffee Break
03:50 PM – 05:00 PM
Young Generation Session II
05:00 PM – 05:15 PM
Closing Remarks
06:00 PM – 09:00 PM Dinner
9|P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Program
June 6, 2014 (Friday)
Registration & Reception
Lobby
5:30 PM - 6:30 PM
Opening Ceremony & Banquet
Ballroom
6:30 PM - 7:40 PM
Coordinator: Jaeyoung Kwak, KSEA-NJ Vice President
Opening Remark:
K. Stephen Suh, KSEA NY Metro Acting President & Jae-Hun Kim, KASBP President
Congratulatory Remarks:
“KSEA Activities in 2014”, Dr. MyungJong Lee, KSEA President
“Government policy & support for Pharmaceutical Industry”, Jeong Hoon WOO, KHIDI USA director-general
Dinner
Seoul National University OB Choir (NY-NJ) Performance
Keynote Speech
Ballroom
7:40 PM - 8:30 PM
“Memoirs of Field Effect Transistors”
Sang-Wook Cheong, Department of Physics, Rutgers University
Sponsor Presentations
Ballroom
8:30 PM - 9:00 PM
“Introduction to Yuhan R&D”, Kyoung Kyu Ahn
Networking
General –Ballroom
IT – Pioneer Room
BT/YG – 2nd Floor Meeting Room
9:00 PM - 12:00 AM
10 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
2nd Floor Meeting Room
BT Small Group Discussion
9:15 PM - 10:15 PM
Small Group Discussion:
Pharma industry –Academia, and Career Development
Moderator: Yong-Hwan Jin, GSK
“The current snap shot of how Koreans are doing in Corporate America: are we maximizing our potential?”
Jino Ahn, Asian Diversity Inc.
2nd Floor Meeting Room
IT Small Group Discussion
9:15 PM - 10:15 PM
Moderator: Seungjoon Lee
Welcoming Remarks
Ken Park (KSEA-NJ) & Myung Jong Lee (KSEA-NY Metro)
June 7, 2014 (Saturday)
Registration & Breakfast
Lobby
8:30 AM ~ 9:00 AM
Coordinators: Chris Lee, BMS,
Alex Kim, Merck
Young Jin Kim, Bell Laboratories
TECHNICAL SESSION
Young Generation (YG) FORUM
YG will participate in BT & IT sessions in the AM of Saturday.
Networking Lunch / Poster Session
Lobby / Pioneer Room
12:10 AM – 2:20 PM
Young Generation Session I
2nd F Meeting Room
11 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
02:20 PM - 03:30 PM
Co-Chairs: Sahee Kim & Dahea Diana You, KSEA-NJ/KASBP YG Co-Directors
Young Generation Introduction
Sahee Kim, Pharm.D. & Dahea Diana You, Pharm.D., KSEA-NJ/KASBP YG Co-Directors
Sharing of Career Experience in the Science Field
Yun H. CHOE, Ph.D.
Soo KANG, DDS
Jaeyoung Kwak, Ph.D.
Q & A Session
PM Coffee Break
Lobby
3:30 PM - 3:50 PM
Young Generation Session II
2nd F Meeting Room
03:50 PM - 05:00 PM
Co-Chairs: Sahee Kim & Dahea Diana You, KSEA-NJ/KASBP YG Co-Directors
Importance of Networking
Dahea Diana You, Pharm.D. & Sahee Kim, Pharm.D.
Early Career Development/Experience as a KSEA YG Member
Jun Hyuk Heo
Group Interactive Session: How to Make the Most Out of Your 20’s/Early 30’s
Closing Remarks
2nd F Meeting Room
05:00 PM - 05:15 PM
Yun H. Choe, KSEA-NJ President
Dinner and Networking
Ichiumi Restaurant
6:00PM -
Ichiumi Restaurant
352 Menlo Park Dr (Menlo Park Mall), Edison, NJ 08837
12 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
(Tel. 732.906.2370)
INFORMATION TECHNOLOGIES FORUM
Information Technology I: Software Defined Networking
Pioneer Room
09:00 AM - 10:30 AM
Chair: Jaeyoung Kwak (Alcatel-Lucent)
“Software Defined Networking”
Young Jin Kim (Alcatel-Lucent)
“Network Function Virtualization and Software Defined Networking”
Seungjoon Lee (AT&T)
AM Coffee Break
Lobby
10:30 AM - 11:00 AM
Information Technology II: Big Data
Pioneer Room
11:00 AM - 12:30 PM
Chair: Young Jin Kim (Alcatel-Lucent)
“Scaling Queries over Big RDF Graphs with Semantic Hash Partitioning”
Kisung Lee (Georgia Tech)
“Finding Hidden Causes of Network Performance Problems in Large Data Set through Anomaly Detection”
Bongjun Ko (IBM T. J. Watson Research Center)
Networking Lunch / Poster Session
Lobby / Grand Ball Room / Pioneer Room
12:30 PM – 1:30 PM
Information Technology III: Cloud Computing and Virtualization
Pioneer Room
1:30 PM - 3:30 AM
Chair: Bongjun Ko (IBM)
“NetVM: High Performance and Flexible Networking using Virtualization on Commodity Platform”
Jinho Hwang (IBM)
13 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
“Virtualization of Multimedia Processing and Communications Engines”
Kyeong Ho Yang (Dialogic)
PM Coffee Break
Lobby
3:30 PM - 4:00 PM
Information Technology IV: Open Discussion – What’s Next?
Pioneer Room
4:00 PM - 5:00 PM
Chair: Kyeong Ho Yang (Dialogic)
Closing Remarks
Pioneer Room
5:00 PM - 5:15 PM
Dong Sung Suk
Dinner and Networking
Ichiumi Restaurant
6:00PM -
Ichiumi Restaurant
352 Menlo Park Dr (Menlo Park Mall), Edison, NJ 08837
(Tel. 732.906.2370)
BIO & PHARMA SCIENCE
Round Table Discussion
Ballroom
7:00 AM ~ 8:30 AM
Moderator: Yun H. Choe, Lucas & Mercanti: Regulatory Perspectives in Drug Approval Process
Opening Remarks and Introduction to Drug Discovery
Ballroom
9:00 AM ~ 9:15 AM
“Innovative drug discovery process: Technology-driven or Science-driven?”
Program Co-chair: Chang-Sun Lee, PTC Therapeutics
Forum A1
Ballroom
9:15 AM ~ 10:25 AM
Chair: Chang-Sun Lee, PTC Therapeutics
“Optimal strategy to identify drug-like molecules in drug discovery”
Jae-Uk Jeong, GSK
14 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
“Effects of hepatic DGAT2 inhibition on lipid and glucose metabolism in obese mice”
Seongah Han, Merck
Coffee Break
Lobby
10:25 AM ~ 10:45 AM
Forum A2
Ballroom
10:45 AM ~ 11:55 AM
Chair: Sean Kim, Novartis
“DMPK/Biopharmaceutics strategy in early drug development”
Saeho Chong, Takeda Pharmaceuticals
“Multifunctional nanoparticle-based drug/gene delivery for stem cell and cancer research”
KiBum Lee, Rutgers University
Fellowship Award Ceremony
Ballroom
11:55 AM ~ 12:10 PM
Chair: Eunsung Junn, Rutgers University
Lunch & Poster Presentation
Ballroom
12:10 PM ~ 2:30 PM
Sponsor Talk 1
Ballroom
2: 30 PM~ 2:45 PM
Special Lecture: Drug Discovery and Development in Korea
Yong-Hae Han
Forum B1
Ballroom
2:45 PM ~ 3:55 PM
Chair: Ik-Hyeon Paik, Melinta Therapeutics
“Statistics in clinical trials and drug development”
Suktae Choi, Celgene
“Basics of Business Development: why partner and how to position your asset”
Minji Kim, Curis
Coffee Break
Lobby
15 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
3:55 PM~ 4:15 PM
Sponsor Talk 2
Ballroom
4:15 PM ~ 4:30 PM
BSRC: Introduction to Bio-Synergy Research Center
Doheon Lee, Bio-Synergy National Research Project
Forum B2
Ballroom
4:30 PM ~ 5:05 PM
Chair: Luke Oh, Questcor
Drug Development from Natural Resources
Eunjung Park, Pharmacologist
Closing Remarks
Ballroom
5:05 PM ~ 5:15 PM
KASBP President: Jae-Hun Kim, IFF
Dinner and Networking
Ichiumi Restaurant
6:00PM -
Ichiumi Restaurant
352 Menlo Park Dr (Menlo Park Mall), Edison, NJ 08837
(Tel. 732.906.2370)
16 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Abstract and Biography
17 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
KEYNOTE SPEECH
Memoirs of Field Effect Transistors
Sang-Wook Cheong
Rutgers University
Abstract: CMOS is the basis of microprocessors with integrated circuits, which are indispensable in our
modern life with computers and smart phones. The full name of CMOS is CMOS-FET, which stands for
complementary metal-oxide-semiconductor field effect transistor - a special type of field effect transistor (FET).
I will review the history of FET, which mingles with Korean heritage, infamous fraud, and also scientific
triumph.”
Biography: Prof. Sang-Wook Cheong has made ground-breaking contributions to
the research field of enhanced physical functionalities in complex materials
originating from collective correlations and collective phase transitions such as
colossal magnetoresistive and colossal magnetoelectric effects in complex oxides. He
has also made pivotal contributions to mesoscopic self-organization in solids,
including the nanoscale charge stripe formation, mesoscopic electronic phase
separation in mixed-valent transition metal oxides, and the formation of topological
vortex domains in multiferroics, which was found to be synergistically relevant to
mathematics (graph theory) and even cosmology. He has published more than 600
scientific papers, and the total citation is more than 35,000 (six papers cited more
than 1000 times, and his h-index is 93). His educational background includes mathematics in college, string theory
(about three years) in graduate school, and solid state physics for Ph. D. He has worked at Los Alamos National
Laboratory, AT&T Bell Laboratories, and Rutgers Center for Emergent Materials (RCEM), Rutgers. He is currently
the director of RCEM, a Board of Governors Professor at Rutgers, and a Distinguished Professor at Postech, Korea.
His work on complex oxides has been recognized through various prizes, including the 2007 Hoam Prize sponsored
by Samsung, the KBS 2009 Global Korean Award, and the 2010 James C. McGroddy Prize for New Materials
sponsored by IBM.
18 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Pharma industry-Academia and Career Development
The current snap shot of how Koreans are doing in Corporate America: are we maximizing our potential?
Jino Ahn, MBA, Asian Diversity Inc
Abstract: What does it take to find the best possible jobs and succeed in reaching the maximum career
potential? Too many Korean students and young professionals mistakenly believe that obtaining a high GPA
from a reputable academic institutions will automatically secure good jobs at major U.S. and international
companies. Similarly, many young professionals think that keeping their heads down and producing good
work will result in promotion and eventually land them at the C-Suite level positions. The reality is far from
it. Korean and Asian students and professionals face extra layer of challenges due to their cultural value
system and lack of information. In this session, you will learn what you need to do to overcome your minority
status and succeed in landing the best jobs and break through the glass ceiling.
Biography: Ahn earned a Bachelor’s degree in Marketing & International Business from New York University
(Stern) and an MBA from Baruch College, with a concentration in Human Resource Management. Ahn has
served in the U.S. Army Reserve achieving the honorable rank of First Lieutenant. He is a Certified Personnel
Consultant and Certified Diversity Consultant. Jino Ahn is the Founder and CEO of Asian Diversity, Inc. (ADI), a
New York City-based company since 1987. ADI is the very first and largest firm in the U.S. that helps U.S.
companies to actively incorporate Asian Americans into their diversity initiatives; for both hiring and
development. Ahn has been a visionary and a pioneer in empowering Pan-Asian Americans in the workplace.
He has led the Asian community’s effort to help Asian American professionals enter and advance in Corporate
America. He is credited for helping put Asian Americans on the diversity map in the U.S.
TECHNICAL SESSION
Young Generation (YG) FORUM
YG Session 1
Co-Chairs: Sahee Kim, RevHealth & Dahea Diana You, Rutgers University
How Many Different Careers Can you Cover with Pharmacy Degree?
Yun H. CHOE, Ph.D., Lucas & Mercanti, LLP
Abstract: When I applied for college, I have never thought that I would be studying law. I am 3rd year in Law
School. When I was studying pharmacy, I did not know that I would study in US and chemistry. When my
company was closing in 2006, I did not know where to go next. We study and make plans with expectation.
19 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
However, sometime, we go through the door open on our way and go through the path where our steps take
us. I went through various positions, teaching Organic Chemistry at Rutgers, Research Scientist and Manager
at Pharmaceutical Companies, and now, consulting and working in patent law field. All of these positions
seem to be different but they are all tightly related. I was a shy graduate student when I first came to US for
my graduate degree. I made so many mistakes and I didn’t know how to handle different situations. I would
like to share my experience of mistakes, frustrations, and results with the KSEA YG.
Biography: Yun H. Choe, Ph.D., received a Bachelor of Science in Manufacturing Pharmacy and a Master of
Science in Medicinal Chemistry from College of Pharmacy of Seoul National University in Seoul, Korea in 1985
and 1987 respectively. She also received a Ph.D. in Synthetic Organic Chemistry from Rutgers, The State
University of New Jersey in 1993. She is currently studying at Fordham University Law School expecting J.D.
2015. After her post-doctoral research at Hoffmann-La Roche, Inc. in Nutley, New Jersey, she worked about 15
years in research and development of Polymer Drugs and Polymeric Drug Delivery Systems at several
companies including Enzon Pharmaceuticals, Inc. & Polymerix Corp. in New Jersey. With her extensive
experience in Research and Development in Pharmaceutical and Medical Device industry, she consults
intellectual property issues and FDA filing issues, including IND filing and OTC registration. Dr. Choe is a
member of several professional organizations, including the Korean-American Scientist and Engineers (KSEA)
served NJ chapter president for 2013-2014, Korean Scientist in Biotech and Pharmaceuticals (KASBP),
American Intellectual Property Law Association (AIPLA), American Chemistry Society (ACS), the American
Association for Cancer Research (AACR), and the Controlled Release Society (CRS). Dr. Choe is also registered
to practice before the United States Patent and Trademark Office. Dr. Choe is currently at Lucas & Mercanti,
LLP, an intellectual property specialized law firm in New York, as a Scientific Advisor, Patent Agent, and IP
Consultant.
Sharing of Career Experience in the Science Field
Soo KANG, DDS, Good Morning Dental, LLC
Abstract: I would like to share my personal background with the attendee to shed some light on the career
path I chose from being a biochemistry major from West coast to a dentist who eventually settled in East coast.
My experiences were very unique in many aspects since most of my classmates who graduated with me from
NYU dental went back to west coast after graduation. I am only one of the few who chose to stay and settle
here. I should say that it was a geographic leap of faith since I have no family members in the East coast.
Financial burdens, cultural differences, big city shocks, etc. will be mentioned. My decision to not open my
own office right way but to study further in a respectable hospital setting will be discussed since residency is
optional not mandatory. Uncertainty of opening up a start-up office will be mentioned along with some pros
and cons of going into a private office setting versus group practice. Many factors in owning a private office
will be disclosed in some details. In addition, market tactics that I used personally will be revealed, and my
professional and personal values will be discussed. Lastly, how I feel about my decision to choose this
particular career and what I would have changed will be mentioned. I will accept questions, both personal and
professional, in an opened discussion.
20 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Biography: Dr. Soo Kang was born 12-10-1972 in Busan, Korea, youngest of three siblings. She moved to US in
1984 and settled in Los Angeles California until 1997. She attended Virgil Junior High and Richard Gahr High
Schools. In 1992 she was accepted in UCLA for Biochemistry major which she graduated in 1996 with a B.S.
degree. She worked briefly in Department of Neuroscience. She moved to NYC in 1997 and attended NYU
College of Dentistry for next 4 years to receive Doctorate of dental surgery. She graduated 2001. Dr. Kang
worked and learned at HUMC, Hackensack University Medical Center General residency. She is married to Mr.
Jun S. Oh and had two Daughter, Emily and Kayla Oh. Dr. Kang owned Soo Kang D.D.S a private dental office in
2007. Currently she is an owner of Good Morning Dental, LLC in Hackensack and a Co-Owner of Union Plaza
Diner and other restaurants. She is supporting a non-profit organization called “Mission for Laos” and would
like to establish a non-profit organization to offer dental treatments for underrepresented minorities and 3rd
world underdeveloped countries with free dental care along with a Christian based mission work in the future
to balance her life as a dentist, a wife, a mother, and a Christian.
Sharing of Career Experience in the IT Field
Jaeyoung Kwak, Ph.D., Alcatel-Lucent
Abstract: I will share my experience in IT field. Since I finished my Ph.D., I worked in three difference
companies with different size and environment. I can share my experience in these different corporations.
Biography: MTS, Alcatel-Lucent 2010 – Present; Murray Hill, NJ; Sr. Staff engineer, InterDigital; Research
Scientist, Telcordia Technologies; PhD, Electrical Engineering, Polytechnic University; 13+years of research and
development experiences for advanced wireless systems after PhD.; Specialties: research and development in
wireless communication area including LTE, TDD/WCDMA, FDD/WCDMA, HSPA, MIMO, OFDM, SC-FDMA.
YG Session 2
Co-Chairs: Sahee Kim, RevHealth & Dahea Diana You, Rutgers University
Importance of Networking
Dahea Diana YOU, PharmD, Rutgers University & Sahee KIM, PharmD, RevHealth, LLC
Abstract: What is networking, why is it important and how do you start it? In this presentation, Young
Generation (YG) co-directors will give an overview of networking process, and share their perspectives about
why they think networking is important as a young professional or a student.
Biography of Diana: Dahea (Diana) You, Pharm.D., graduated as a Doctor of Pharmacy in May 2014 from
Ernest Mario School of Pharmacy at Rutgers University. During her pharmacy program, she actively
participated in various activities and organizations including undergraduate admissions, Center for Global
services, and professional pharmacy associations as a student leader. After completing Pharmacy Honors
Research Program at Rutgers, she decided to pursue her career in research. As a part of Pharm.D./Ph.D. dual
degree program at Rutgers University, she is currently continuing her education in a graduate program in
21 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Toxicology. In addition to her academic work, she has continued to get actively involved by serving as a YG CoDirector for KSEA-NJ and KASBP.
Biography of Sahee: Sahee Kim, Pharm.D., graduated as a Doctor of Pharmacy in May 2013 from Ernest Mario
School of Pharmacy at Rutgers University. Through a valuable internship at Daewoong Pharmaceutical Co., Ltd.
during the summer of 2010, she became interested in pursuing a career path in pharmaceutical marketing.
After an externship at RevHealth, LLC, a pharmaceutical advertising agency, she is currently working as a
medical writer at the agency. Leveraging her various leadership experience and passion for serving KoreanAmerican community, she has been actively volunteering as a teacher at a Korean Sunday School and a YG CoDirector for KSEA-NJ and KASBP.
Networking among Korean-Americans? Melting Pot of Generatiions.
Mr. Jun Hyuk HEO, Merck
Abstract: It is common for students and young professionals to struggle in deciding what career path they
want to take and how to get to that career path. People I met during my internship and KSEA meetings helped
me define my goals and guided me through some of the most important moments of my career path. I’d like
to share my experience in early career development to encourage people to network and participate in KSEA
activities.
Biography: Jun Hyuk Heo is an analytical scientist at Merck Research Laboratories. He graduated from Drexel
University in 2010 with a Bachelor’s Degree in Biomedical Engineering. He is currently working full-time at
Merck and studying part-time at Columbia University for Masters in Biomedical Engineering.
****************************************************
INFORMATION TECHNOLOGIES FORUM
Session I: Software Defined Networking
Chair: Jaeyoung Kwak (Bell Laboratories)
Software Defined Networking
Young Jin Kim, Bell Laboratories
Abstract: Today, many communication systems run at only 10-20 percent of utilization. This tremendous
waste arises from difficulties interworking with legacy systems, unique requirements and deployment issues
as well as the overarching need to plan for rare instances of peak demand. Software Defined Networking (SDN)
and Network Function Virtualization (NFV) technologies simplify the deployment and management of existing
and envisioned applications and services. State-of-the-art techniques in the SDN/NFV domain create
dynamically adaptable virtual network slices to cost-effectively and securely meet the application needs, e.g.,
22 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
the scalable deployment of present and future applications with varying requirements on security and timecriticality. In short, SDN/NFV-based solutions replace existing costly custom built dedicated hardware and
software components with an infrastructure that can allocate resources on-demand over a pool of
dependable, dynamically contracted communication resources. The elasticity provided by the SDN/NFV allows
the network service providers to leverage significant investments in their own networks and resources outside
of the service provider's boundaries.
Biography: Young-Jin Kim is a Member of Technical Staff of Network Algorithms, Protocols, and Security
(NAPS) Department at Bell Labs, Alcatel-Lucent, Murray Hill, NJ. Dr. Kim received a Doctorate in Computer
Science from University of Southern California and his B.S./M.S. degree in Computer Science from Yonsei
University respectively. By 2007, He had worked as a senior software engineer at Samsung Electronics
Telecommunication R&D center, Korea. Since joining Bell Labs in 2010, he have been contributing to machineto-machine communications for cyber-physical systems such as Smart Grids. His work typically involves the
secure and self-configurable system design for large-scale network applications. His current research interests
include network algorithms and secure protocols for software-defined networks and virtualized network
infrastructures. His research has been published in IEEE/ACM conference proceedings and journals, and has
been distributed as publicly-available software.
Network Function Virtualization and Software Defined Networking
Seungjoon Lee, Principal Member of Technical Staff, AT&T Labs – Research
Abstract: Although I am just an engineer, I want to share my story and my insight with hope that they will
help your future decisions. In my presentation, I will share my career experience and different career paths
you can take as an engineer that I did not know in the beginning of my journey that might have taken me to a
better journey. First, to encourage YG members to stay in the engineering field, I want to talk about my
journey: what life is like as an engineer. You can hear about a simple life as an engineer that people typically
expect. However, I know many people who pursued a different direction in their career paths, although they
were engineers at the beginning. If someone gave me those insights at the beginning of my journey, I might
have changed my career direction to do something I’m more interested in doing. Therefore, in hope that
people will not make the same mistake, I want to share what kind of different directions you can take in the
future with an engineering background. However, my conclusion is that you are the only one who could make
decisions about your career path, and not your parents or others around you. You have to take a deep breath
and think seriously about what you are interested in, what you want to achieve in your life, etc. Another
important thing is “Do not hesitate to pursue you dream,” when you make a decision about your future. If you
neglect to take the step to pursue your dream, you will never achieve what you want. Hesitating will only bring
regrets to your mind, and in my opinion, that is worse than facing failures with the direction you decided to
take. I wish that my story will give you a new insight for your future decisions.
Biography: Jaeyoung Kwak, Ph.D. is a Member of Technical Staff in Alcatel-Lucent, Murray Hill, NJ. He is
currently developing various algorithms for the base station. He received a Ph.D. in Electrical Engineering from
Polytechnic University in Brooklyn, New York. He received M.S. in Electrical Engineering from Northwestern
University in Evanston, IL and B.S. in Electronics and Computer Engineering from Korea University in Seoul,
23 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Korea, respectively. Before joining in Alcatel-lucent, he has been working on participating in standardization
and developing various receiver algorithms for current and future wireless communications in Telcordia and
InterDigital. His research interests include advanced signal processing, energy efficient receivers, and crosslayer optimization for current and future wireless communications.
Session II: Big Data
Chair: Young Jin Kim (Bell Laboratories)
Finding hidden causes of network performance problems in large data set through anomaly detection
Bongjun Ko, Research Staff Member, IBM T. J. Watson Research Center
Abstract: I will present how anomaly detection techniques can be effectively used to find hidden causes of
the network performance problems. By applying the principle of partitioning the given data set into several
groups based on ``situational similarities'', and then by finding out the outliers in each group through
statistical anomaly detection mechanisms, our analytical framework enables parallel processing of large data
set representing the performance of large system. I will show the effectiveness of our approach in the context
of analyzing call quality data generated in cellular wireless network.
Biography: Bongjun Ko is a research staff member and a research manager in Cloud-based Networking
department at IBM T. J. Watson Research Center. He received a Ph.D. in Electrical Engineering from Columbia
University in 2006, and B.S. and M.S. degrees from Seoul National University in South Korea. His research
interests include data analytics, cloud computing, mobile networking, and distributed systems.
Scaling queries over big RDF graphs with semantic hash partitioning
Kisung Lee, Ph.D. Candidate, College of Computing at Georgia Tech
Abstract: Massive volumes of big RDF data are growing beyond the performance capacity of conventional RDF
data management systems operating on a single node. Applications using large RDF data demand efficient
data partitioning solutions for supporting RDF data access on a cluster of compute nodes. In this paper we
present a novel semantic hash partitioning approach and implement a Semantic HAsh Partitioning-Enabled
distributed RDF data management system, called Shape. This paper makes three original contributions. First,
the semantic hash partitioning approach we propose extends the simple hash partitioning method through
direction-based triple groups and direction-based triple replications. The latter enhances the former by
controlled data replication through intelligent utilization of data access locality, such that queries over big RDF
graphs can be processed with zero or very small amount of inter-machine communication cost. Second, we
generate locality-optimized query execution plans that are more efficient than popular multi-node RDF data
management systems by effectively minimizing the inter-machine communication cost for query processing.
Third but not the least, we provide a suite of locality-aware optimization techniques to further reduce the
partition size and cut down on the inter-machine communication cost during distributed query processing.
Experimental results show that our system scales well and can process big RDF datasets more efficiently than
existing approaches.
24 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Biography: Kisung Lee is a Ph.D student in the College of Computing at Georgia Tech. He received his BS and
MS degree in computer science from KAIST in 2005 and 2007 respectively. He had worked for ETRI as a
researcher from 2007 to 2010. He is conducting research in big data management in the Cloud, mobile
computing and social network analysis. Currently, he is working for IBM T.J. Watson Research Center as a
research intern.
Session III: Cloud Computing and Virtualization
Chair: Bongjun Ko (IBM)
NetVM: High Performance and Flexible Networking using Virtualization on Commodity Platform
Jinho Hwang, Research Scientist, IBM T. J. Watson Research Center
Abstract: NetVM brings virtualization to the Network by enabling high bandwidth network functions to
operate at near line speed, while taking advantage of the flexibility and customization of low cost commodity
servers. NetVM allows customizable data plane processing capabilities such as firewalls, proxies, and routers
to be embedded within virtual machines, complementing the control plane capabilities of Software Defined
Networking. NetVM makes it easy to dynamically scale, deploy, and reprogram network functions. This
provides far greater flexibility than existing purpose-built, sometimes proprietary hardware, while still
allowing complex policies and full packet inspection to determine subsequent processing. It does so with
dramatically higher throughput than existing software router platforms.
NetVM is built on top of the KVM platform and Intel DPDK library. We detail many of the challenges we have
solved such as adding support for high-speed inter-VM communication through shared huge pages and
enhancing the CPU scheduler to prevent overheads caused by inter-core communication and context
switching. NetVM allows true zero-copy delivery of data to VMs both for packet processing and messaging
among VMs within a trust boundary. Our evaluation shows how NetVM can compose complex network
functionality from multiple pipelined VMs and still obtain throughputs up to 10 Gbps, an improvement of
more than 250% compared to existing techniques that use SR-IOV for virtualized networking.
Biography: Dr. Jinho Hwang recently joined IBM Research after the graduation from The George Washington
University. His research focuses on resource management of high performance data centers and cloud
platforms utilizing virtualization technologies to improve management, reliability, and performance efficiency.
Virtualization of Multimedia Processing and Communications Engines
Kyeong Ho Yang, Director, Video technologies, Dialogic Inc.
Abstract: This presentation discusses recent trends of multimedia processing on the network including
virtualization of multimedia processing and communications engines and its advantages and potential issues.
It also covers the most recent trend in the real time multimedia - WebRTC that harnesses the power of video,
voice and data as built-in real-time communication features of browsers such as Google Chrome and Mozilla
Firefox. Lowering barriers to multimedia communication services on both client and application sides of the
25 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
service delivery equation, WebRTC simplifies the integration of interactive video, voice and data
communications in a wide range of solutions and on many new dimensions.
Biography: Kyeong Ho Yang leads research and development efforts of Dialogic in the fields of video
processing and multimedia communication systems as Chief Video Architect and Director of Video
Technologies. He has about 20 years of R&D and product development experience at companies of various
sizes from start-ups to R&D Labs of large companies like Bell Laboratories, where he developed multiple video
coding and transcoding products including H.261, H.263, MPEG4, MPEG2, H.264 and VPx codecs while
generating more than 50 (peer-reviewed) conference/journal papers and 11 US patents with 9 pending. He
has a proven track record of managing R&D teams to deliver video products to the market starting from a
research stage, 3rd-party software, or an open source code. His expertise in video coding platform includes
multi-core CPU, GPU, and real-time software for DSP. While focusing on the core technology developments,
Dr. Yang also enjoys working closely with other internal organizations (engineering, testing, marketing and
sales) and external customers. His main interest these days is emerging multimedia services in the broadband
mobile environment, and he focuses on development of algorithms and quality optimization of the entire
service system to provide the best possible multimedia quality of experience to the user. Applications of
interest include video conferencing, video streaming, and multimedia apps on mobile devices.
Session IV: Open Discussion – What’s Next?
Chair: Kyeong Ho Yang (Dialogic)
************************************************
BIO & PHARMA SCIENCE
Forum A1
Optimal strategy to identify drug-like molecules in drug discovery
Jae Uk Jeong, Ph.D., GlaxoSmithKline
Abstract: The guideline to identify candidate molecules with the concept of drug-like properties has been
widely applied in drug discovery and development since the late 1990's. In this presentation, a couple of key
aspects from recent efforts in GlaxoSmithKline will be discussed along with a couple of practical examples.
Biography: Senior Scientific Investigator, GlaxoSmithKline, 1998 ~ present; Postdoctoral research associate,
Department of Chemistry, The Scripps Research Institute, 1996 ~ 1998; Research scientist, Korea Institute of
Science and Technology (KIST), Seoul, Korea, 1989 ~ 1991. Ph.D., Organic Chemistry, Purdue University, May
1996; M.S., Organic Chemistry, Sogang University, Seoul, Korea, February 1988; B.S., Chemistry, Sogang
University, Seoul, Korea, February 1986.
26 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
The effects of DGAT2 inhibition on glucose and lipid metabolism
Seongah Han, Ph.D., Merck Research Laboratories
Abstract: DGAT2 (Acyl-CoA: diacylglycerol acyl transferase) catalyzes the final step in triglyceride (TG)
synthesis, and has been gaining attention for a proposed role in diabetes and metabolic syndrome. DGAT2
plays a role in regulating hepatic VLDL production and its inhibition has been considered as a potential
therapeutic strategy for atherosclerosis via decreased VLDL and LDL. Insulin resistance, hyperglycemia,
hepatosteatosis and dyslipidemia characterized by increased plasma triglyceride and reduced HDL are
contributing factors for accelerating atherosclerosis in diabetes and metabolic syndrome. To study the
hypothesis that hepatic DGAT2 inhibition would reduce hepatic TG synthesis, improve hepatosteatosis and
insulin sensitivity, we generated AAV-mediated DGAT2 knockdown (AAV-shDGAT2) in growing diet induced
obesity (gDIO) mouse model. We also administered the DGAT2 inhibitor to gDIO mouse model to test the
systemic effects of DGAT2 inhibition. Both hepatic and systemic inhibition of DGAT2 significantly reduced
newly synthesized TG, hepatic lipid contents, and reduced plasma LDL cholesterol levels without changing
body weight. Despite these dramatic lipid changes, both AAV-shDGAT2 and DGAT2 inhibitor treated gDIO
mice showed similar plasma insulin, glucose levels and glucose tolerance test responses compared to controls.
Further studies exploring the effects of DGAT2 modulation on glucose and lipid metabolism are warranted.
Biography: Senior Scientist, Merck Research Laboratories, Kenilworth, NJ, 2009 – present; Associate Research
Scientist, Department of Medicine, Columbia University, NY, 2005 – 2009; Postdoctoral Research Fellow,
Department of Medicine, Columbia University, NY, 2002 – 2005; Ph.D., Genetics, University of California, Davis
(2002). M.S., Agronomy, University of California, Davis (1995); B.S., Agronomy, Kyung Hee University, Yongin,
South Korea (1991).
Forum A2
DMPK/Biopharmaceutics Strategy in Early Drug Development
Saeho Chong, Ph.D., Takeda Pharmaceuticals
Abstract: Compound advancement during drug discovery involves balancing pharmacological potency against
selectivity, safety and ADME/PK properties. Based on this multifactorial optimization, tradeoffs are often
made, leading to drug candidates with poor biopharmaceutic parameters (i.e., low solubility and poor
permeability). Poor biopharmaceutic properties can lead to incomplete absorption and variable
pharmacokinetics, which in turn make it difficult to establish a dose-response relationship. In the worst-case
setting, these limitations may lead to delayed developments timeline and a higher pharmaceutical cost during
development to overcome the poor biopharmaceutic properties. A proactive approach to assessment of
biopharmaceutical properties (at the candidate selection and early development stages) and mitigation of
identified risks is thus warranted. Biopharmaceutic strategy to build in developability for oral drug candidates
can be applied at various stages of discovery and development. For early discovery stage, viable chemical
scaffolds can be evaluated and prioritized with respect to biorelevant solubility and permeability using a HTS
27 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
approach, integrated with in silico predictive models. For late discovery stage (lead optimization), a more
integrated system such as in vitro diffusion chamber model where biorelevant solubility and membrane
permeability are simultaneously evaluated can be used to identify a primary rate limiting factor (i.e., solubilitylimited vs. permeability-limited), if any, during absorption. For early development stage, both in vivo and in
vitro models are fully utilized to evaluate optimal formulation, particle sizes, salt forms, pH-dependent
absorption, and potential food effect. A few examples will be discussed to illustrate the importance of
biopharmaceutics strategy.
Biography: Director, DMPK, Takeda Pharmaceuticals Company, Cambridge, MA, 2012 ~ present; Professor,
College of Pharmacy, Seoul National University, Seoul, Korea, 2009 ~ 2012; Head of DMPK, BMS, 1990 ~ 2009.
Ph.D. (Pharmaceutics), Department of Pharmaceutics, SUNY at Buffalo, Amherst NY (1988); B.S.
(Pharmaceutics), Department of Pharmaceutics, SUNY at Buffalo, Amherst NY (1982).
Multifunctional nanoparticle-based drug/gene delivery for stem cell and cancer research
KiBum Lee, Ph.D., Rutgers University
Abstract: This talk will focus on developing methods for synthesizing multi-functional nanoparticles (i.e.
multimodal imaging agents, target-specific drug delivery vehicles and stimuli-responsive drug delivery systems)
and utilizing the functional nanomaterials as novel genetic manipulation tools for controlling cancer/stem cell
behaviors. The successful application of cancer/stem cell therapy requires development of novel methods of
genetic as well as cellular engineering aimed at efficient activation or inhibition of specific cellular functional
genes, proteins, and signaling pathways. To this end, targeted delivery of either a single biomolecule (e.g.
small organic molecules, proteins, and RNAi molecules) or a combination of biomolecules using non-viral
intracellular delivery would be attractive. Unique properties of nanomaterials endow the nanoparticle-based
drug delivery systems with the capability to regulate and interact with biological targets (e.g. proteins and cells)
in a controlled manner for inducing the desired physiological responses. In this presentation, a summary of the
most updated results from these efforts and future directions will be discussed.
Biography: Associate Professor, Dept. of Chemistry and Chemical Biology, Rutgers University, 2013 ~ present;
Assistant Professor, Dept. of Chemistry and Chemical Biology, Rutgers University, 2008 ~ 2013; PostDoc,
Chemical Biology, The Scripps Research Institute, La Jolla, CA, 2004~2007. Ph. D., Chemistry, Northwestern
University, Evanston, IL, 2004; M. S., Physical Chemistry, KAIST, Taejon, Korea, 2000; B. S., Chemistry, Kyung
Hee University, Seoul, Korea, 1998.
Forum B1
Statistician’s role in clinical trials and drug development; beyond the sample size and p-value calculation
Suktae Choi, Ph.D., Celgene
Abstract: Statistics is the art/science of summarizing and interpreting data so that non-staticians can
understand it. The punch-lines (Does the new drug efficient and safe?) of the clinical trials are mostly based on
28 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
statistical inference. However, the statistician’s role in the clinical trial is not only calculating sample size or
providing analysis results including confidence intervals and p-values. In these days of the pharmaceutical
world, it is hard to imagine a drug development plan and process without an input of statistical perspective in
every single aspect. In this presentation, a high-level summary of pharmaceutical company’s clinical
development plans on Phase I–IV and FDA’s review process will be introduced, especially focused on
statistician’s role.
Biography: Dr. Suktae Choi has 16 years of experience in the clinical trial area beginning with his employment
as a project statistician of Organon, Inc. In 2000, he moved into Center for Drug Evaluation and Research, US
FDA as Mathematical Statistician. During 7+ years with the FDA, he reviewed many clinical trials in analgesic,
arthritis, ophthalmic, and anti-viral area submitted for approval of drug indication. He joined Eli-Lilly and
Company in 2007 as Sr. Research Scientist, leaded Byetta statistics group. In 2010, he joined Celgene as
Associate Director, and currently leading the Early Phase of Immunology & Inflammatory Biostatistics Group.
The research areas that he is interested in are multivariate survival analyses, multiple comparisons, missing
data imputations and visualization of safety and early phase data. He published statistical articles in statistics
and medical journals and presented in public. He received Bachelor’s degree of Mathematics from Sogang
University in South Korea, Master’s degree of Statistics from Michigan State University, and also received Ph.D.
degree of Statistics from Rutgers University in 1998.
Basics of Business Development: why partner and how to position your asset
Minji Kim, Ph.D., Curis
Abstract: The pharmaceutical drug development environment has gone through tremendous changes over
the last decade. One of the noticeable phenomena is increasing demands for partnerships with a growing
realization that a single company cannot efficiently develop a drug throughout the whole value
chain. Collaborations between multinational pharmaceutical companies, and pharmaceutical and biotech
companies as well as with academic institutes are more and more critical to bring next generation
therapeutics to the market. The talk will cover some of the current trends in the biopharmaceutical industry,
focusing on the deal environment, to emphasize the importance of the life science ecosystem and
partnership. In addition, for companies which look for partners to develop their internal programs together,
high level strategies about how to position your program, identify potential partners and best out-license your
asset will be discussed.
Biography: Director, Corporate & Business Development, Curis, INC (2013-present); Technical Scout,
Hoffmann-La Roche , INC Business Development & Licensing (2011-2013); MBA, Yale School of Management
(2011); Post-doc, Instructor, Massachusetts General Hospital, Harvard Medical School (2003-2009). Ph.D.,
Molecular and Cell Biology, Seoul National University (2001); M.S., Molecular and Cell Biology, Seoul National
University (1996); B.S., Molecular Biology, Seoul National University (1994).
29 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Forum B2
Drug Development from Natural Resources
Eunjung Park, Ph.D., Pharmacologist
Abstract: The natural drug product is defined as a drug product that is being developed from natural
resources such as plants and animals. It has been extensively used in Asia and Europe. Although it has received
significant public attention, there are only handful approved drugs from natural resources in the US market,
for example, sinecatechins, crofelemer, omega-3-acid ethyl esters, and conjugated estrogen.
The US FDA published the guidance for industry: botanical drug products in 2004. Even though the guidance
gives the current FDA thinking on botanical drugs, it may be used for any multicomponent drugs from natural
resources. Botanical products are finished and labeled products that contain plant matter as ingredients. The
botanical drug is a botanical product intended for use as a drug which targets diagnosing, mitigating, treating
or curing disease. It should be noted that a dietary supplement is often misconceived as a botanical drug but it
is closed to food, not a drug. The unique features of botanical drugs compared to typical synthetic chemicals
are (1) complex mixtures, (2) lack of a distinct active ingredient and (3) prior human use. These play a role as
pros and cons in the aspect of botanical drug development. As of May 2014, there are only two approved
botanical drugs, namely sinecatechins and crofelemer. In general, botanical drugs have the same review
processes as those of synthetic drugs and review division of FDA is determined based on the proposed
indication. The botanical specific issues on drug development are mainly related to the drug quality such as
drug identity, purity, strength, potency, and consistency. Most of these product quality issues can be
addressed by the development of bioassays to ensure its quality, justification in the botanical review and
compliance reviews. The characteristics of current approved botanical drugs are: 1) the indications are highly
specific, and 2) the systemic exposure of both products is very limited as they can be largely considered locally
acting drugs. Meanwhile, the indications of fish oils are relatively broad and they target the systemic exposure
for their actions.
In conclusion, taking into account of large number of botanical drug candidates under development and the
fact that experiences at botanical drugs have accumulated, the development of botanical drug is vastly
evolving.
Biography: Pharmacologist; Scientist, EntreMed, Inc., Rockville, MD; Post-doctoral research associate,
National Cancer Institute, Frederick, MD; Ph.D. School of Pharmacy, Seoul National University; M.S. School of
Pharmacy, Seoul National University; B.S. School of Pharmacy, Ewha Womans University.
************************************************
30 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
POSTER SESSION
KASBP-Hanmi, KASBP-Yuhan & KASBP-KSEA Fellowship Awards
Mitochondrial Hsp90 control of tumor bioenergetics
Young Chan Chae, Ph.D., Wistar Institute
All cells consume nutrients to generate ATP to maintain homeostasis, however cancer cell growth and
maintenance requires additional nutrient uptake to support macromolecular synthesis needed for cell growth.
And cancer cell requires ability to adapt and maintain their active metabolism to multiple different
environmental stresses such as oxygen and glucose limitation, and low pH condition. However, it is still
unknown how metabolic pathways of tumor are regulated and successfully adapt to environmental stress.
Here, we show that Heat Shock Protein 90 (Hsp90)-directed protein folding in mitochondria, but not cytosol, is
required to maintain energy production and stress response to promote tumor cell survival and growth.
Interference with this process activates a signaling network that involves phosphorylation of nutrient-sensing
AMP-activated kinase (AMPK), inhibition of rapamycin-sensitive mTOR complex 1 (mTORC1), induction of
autophagy, and expression of an endoplasmic reticulum (ER) unfolded protein response (UPR). This signaling
network confers a survival and proliferative advantage to genetically disparate tumors, and correlates with
worse outcome in lung cancer patients. Therefore, mitochondrial HSP90s are adaptive regulators of tumor
bioenergetics, and tractable targets for cancer therapy.
Intrinsic Conformational Plasticity of Native EmrE Provides a Pathway for Multidrug Resistance
Min-Kyu Cho, Ph.D., New York University
EmrE is a multi-drug-resistant efflux pump with specificity to a wide range of antibiotics and antiseptics. To
obtain atomic-scale insight into the attributes of the native state that encodes the broad specificity, we used a
hybrid of solution and solid-state NMR methods in lipid bilayers and bicelles. Our results indicate that the
native EmrE dimer oscillates between inward and outward facing structural conformations at a rate of ~300 s-1
at 37 °C (millisecond motions), which is ~50-fold faster relative to the tetraphenylphosphonium (TPP+)
substrate-bound form of the protein. These observables provide quantitative evidence that the rate-limiting
step in the TPP+ transport cycle is not the outward␣inward conformational change in the absence of drug. In
addition, using differential scanning calorimetry, we found that the width of the gel-to-liquid crystalline phase
transition was 2 °C broader in the absence of the TPP+ substrate versus its presence, which suggested that
changes in transporter dynamics can impact the phase properties of the membrane. Interestingly,
experiments with cross-linked EmrE showed that the millisecond inward-open to outward-open dynamics was
not the culprit of the broadening. Instead, the calorimetry and NMR data supported the conclusion that faster
time scale structural dynamics (nanosecond-microsecond) were the source and therefore impart the
conformationally plastic character of native EmrE capable of binding structurally diverse substrates. These
findings provide a clear example how differences in membrane protein transporter structural dynamics
31 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
between drug-free and bound states can have a direct impact on the physical properties of the lipid bilayer in
an allosteric fashion.
Oct-1 regulates IL-17 expression by directing interchromosomal associations in conjunction
with CTCF in T cells
Lark Kyun Kim, Ph.D., Yale University
Interchromosomal associations can regulate gene expression but little is known about the molecular basis of
such associations. In response to antigen stimulation, naïve T cells can differentiate into Th1, Th2 and Th17
cells expressing IFN-, IL-4 and IL-17, respectively. We previously reported that in naïve T cells, the IFN- locus
is associated with the Th2 cytokine locus. Here we show that the Th2 locus additionally associates with the IL17 locus. This association requires a DNase I hypersensitive region (RHS6) at the Th2 locus. RHS6 and the IL-17
promoter both bear Oct-1 binding sites. Deletion of either of these sites or Oct-1 gene impairs the association.
Oct-1 and CTCF bind their cognate sites cooperatively and CTCF-deficiency similarly impairs the association.
Finally, defects in the association lead to enhanced IL-17 induction. Collectively, our data indicate Th17 lineage
differentiation is restrained by the Th2 locus via interchromosomal associations organized by Oct-1 and CTCF.
Cell to cell coupling in dorsal root ganglion (DRG) neurons amplifies pain sensation
Yu Shin Kim, Ph.D., Johns Hopkins University
Hyperalgesia/allodynia, heightened pain sensitivity in uninjured and/or injured tissues, is widely accepted to
be mediated primarily by sensitization of spinal cord and brain neurons, a process called central sensitization.
The contribution of peripheral sensitization of primary sensory neurons to hyperalgesia/allodynia remains
controversial and largely unknown. Here we have generated Pirt-GCaMP3 mice in which GCaMP3, a geneticencoding Ca2+ sensitive indicator, is expressed robustly and specifically in almost all primary sensory neurons.
The advantages of GCaMP3 imaging using these mice include facile, parallel direct visualization of activity in
many afferents, excellent spatial resolution, and preservation of somatotopic organization. Application of this
technique to DRG hyperalgesia/allodynia and inflammatory model permitted us to visualize robust increase of
neuronal hypersensitivity in cell bodies of DRG neurons in vivo in an anesthetized Pirt-GCaMP mouse.
Peripheral sensitization was observed not only as of increasing activated number of neuronal cell bodies in
DRG but also as of apparently increasing cell to cell coupling events. Gap junctions are specialized
transmembrance channels that allow rapid electrical signaling and direct intercellular communication for
maintenance and coordination of normal cellular activities and homeostasis. Strikingly, augmentation in cell to
cell coupling in DRG was mediated by the dynamic plasticity of gap junctions in response to nervous system
injury and modulated neuronal hypersensitivity and pain in animal models of inflammatory and/or sciatic
nerve chronic constriction model (SN-CCI). Blockade of gap junction modulated DRG cell to cell coupling and
also chronic and inflammatory pain and is the potential target as a novel modality for the treatment of
intractable pain syndromes. Pirt- GCaMP3 mice thus represent a unique tool with which to visualize primary
sensory neuron activity under physiological and pathological conditions of pain, itch, and any
somatosensations in vivo and to reveal peripheral sensitization mechanisms associated with hyperalgesia,
allodynia, and possibly referred pain. Therefore, this study creates a new way of characterizing the
32 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
physiological properties and functions for developing new pain- or other modality-specific drug target for a
treatment with few side effects.
High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening
Seouk Joon Kwon, Ph.D., Rensselaer Polytech Institute
Differential expression of various drug-metabolizing enzymes (DMEs) in the human liver may cause deviations
of pharmacokinetic profiles, resulting in interindividual variability of drug toxicity and/or efficacy. Stable cell
lines expressing DMEs are emerging tools for prediction of these clinical events. However, it is difficult to
create and maintain a library of stable cell lines that mimics the diversity of metabolic profiles that give rise to
unexpected outcomes. To address this need, we have developed a “Transfected Enzyme and Metabolism Chip”
(or TeamChip) for high-throughput analysis of systematic drug metabolism and toxicology. The TeamChip is
prepared by delivering genes into miniaturized three-dimensional cellular microarrays on a micropillar chip
using recombinant adenoviruses in a complementary microwell chip. The device enables users to manipulate
the expression of individual and multiple human metabolizing- enzyme genes (such as CYP3A4, CYP2D6,
CYP2C9, CYP1A2, CYP2E1 and UGT1A4) in THLE-2 cell microarrays. To identify specific enzymes involved in
drug detoxification, we created 84 combinations of metabolic-gene expressions in a combinatorial fashion on
a single microarray. Thus, the TeamChip platform can provide critical information necessary for evaluating
metabolism-induced toxicity in a high-throughput manner
Typhoid toxin: Conferring systemic virulence to Salmonella Typhi
Jeongmin Song, Ph.D., Yale University
Salmonella enterica serovar Typhi (S. Typhi) differs from most other salmonellae in that it causes a lifethreatening systemic infection known as typhoid fever. The molecular bases for its unique clinical presentation
are unknown. Here we find that the systemic administration of typhoid toxin, a unique virulence factor of S.
Typhi, reproduces many of the acute symptoms of typhoid fever in an animal model. We identify specific
carbohydrate moieties on specific surface glycoproteins that serve as receptors for typhoid toxin, which
explains its broad cell target specificity. We present the atomic structure of typhoid toxin, which shows an
unprecedented A2B5 organization with two covalently linked A subunits non-covalently associated to a
pentameric B subunit. The structure provides insight into the toxin's receptor-binding specificity and delivery
mechanisms and reveals how the activities of two powerful toxins have been co- opted into a single, unique
toxin that can induce many of the symptoms characteristic of typhoid fever. These findings may lead to the
development of potentially life-saving therapeutics against typhoid fever.
A new driver of aging: the reorganization of chromatin by DNA damage
Jae-Hyun Yang, Ph.D., Harvard Medical School
A long held theory is that aging is caused by the accumulation of mutations. Recent work, however, has shown
that changes to the epigenome may be equally important. Here, we propose a new hypothesis, termed the
“redistribution of chromatin modifiers” (RCM), suggesting these two processes are intimately linked.
According to this hypothesis, DNA breaks cause the redistribution of chromatin modifying proteins away from
33 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
gene promoters to DNA repair sites, causing a reorganization of chromatin. One of these proteins is SIRT1, a
histone-modifying enzyme that serves a dual function in epigenome regulation and DNA repair. There is
increasing evidence that as we age, DNA damage induces the redistribution of chromatin modifiers across the
genome, including SIRT1, resulting in a permanent change in the chromatin landscape and gene expression
patterns that drive the aging process. To test this hypothesis for the first time in vivo, we have generated a
transgenic mouse that conditionally expresses I-PpoI, a slime-mold endonuclease that cuts the mouse genome
at only a few sites within non-coding regions. We will test the impact of transient, non-mutagenic breaks on
the genome-wide redistribution of chromatin modifiers and their effect on chromatin landscape, gene
expression patterns. We will ultimately identify susceptible epigenomic loci and test the ability of drugs that
alter the epigenome (e.g. SIRT1 activators) to reverse the aberrant epigenomic state and aging.
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang, Ph.D., Columbia University
Ferroptosis is a form of non-apoptotic cell death for which key regulators remain unknown. Here, we
identified 12 ferroptosis-inducing (FIN) small molecules and sought a common mediator of their lethality. We
used targeted metabolomic profiling to discover that depletion of glutathione causes inactivation of
glutathione peroxidases (GPXs) in response to one class of FIN compounds. A chemoproteomics strategy
identified glutathione peroxidase 4 (GPX4) as the relevant protein target of a second class of FIN compounds.
GPX4 overexpression and knockdown modulated the lethality of 12 ferroptosis inducers, but not of 11
compounds with other lethal mechanisms highlighting the specific regulation of ferroptosis by GPX4. Stronger
GPX4 knockdown was lethal to cancer cells sensitive to FIN compounds, phenocopying their activity. In
addition, two representative ferroptosis inducers prevented tumor growth in xenograft mouse tumor models
suggesting that targeting ferroptosis may be a feasible strategy to treat cancer. Sensitivity profiling in 177
cancer cell lines from diverse tissue origins revealed that diffuse large B-cell lymphomas and renal cell
carcinomas are particularly susceptible to GPX4-regulated ferroptosis. Thus, GPX4 is an essential regulator of
ferroptotic cancer cell death.
Synthesis of Cell Penetrating Peptides for Drug Delivery Applications
Keun-woo Jin, Ph.D., Temple University
Cell penetrating peptides (CPPs) actively transport into mammalian cells across the plasma membrane (lipid
bilayer) barrier. CPPs are commonly derived from proteins such as the HIV-1 transcriptional activator (TAT)1,
the Antennapedia homeodomain (Antp)2, and the murine vascular endothelial cadherin (pVEC)3. The lengths
of CPPs typically range from 30-50 amino acids and such lengths can lead to preparative challenges since solid
phase peptide synthesis (SPPS) methods4,5 are (commonly) utilized for their preparation. In this presentation,
we will introduce a new short CPP (<10- mer) that cell penetrates not only in soluble conditions but also in gellike conditions. The CPP peptide B (PepB)6 increased cellular uptake of multiple model peptides in a
synergistic manner when combined with other small molecules.
Dye-labeled model (bioactive) peptide A (PepA) was modified with lipid tails or CPP PepB and the uptake
efficiencies were studied in HEK293 cells. The results suggest that PepA internalization synergistically
improved when PepB was combined with lipid molecules (Figure 1). Furthermore, PepB improved the
34 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
solubility of the final product. We, in addition, observed that CPP PepB incorporating molecules stay in the
cytosol of neural stem cells (ReNcell VM) for up to 4 months in culture conditions. We envision utilization of
PepB-incorporating bioactive molecules as potential cellular tagging agents as well as vehicles for drug
delivery applications.
All Posters
Regulation of cell proliferation and senescence by microRNA-4436
Joon-Ho Cho, Ph.D., The George Washington University Medical Center
Background: The microRNAs (miRNAs) negatively regulate gene expression by degrading mRNA and inhibiting
translation of proteins. Recent studies have demonstrated critical role of miRNAs in pathological processes
such as aging and cancer. The miRNAs target various genes that are involved in cell proliferation, senescence,
differentiation and apoptosis. We have been studying regulation of cell proliferation and senescence by the
Polycomb group protein BMI1. We have identified several miRNAs that are regulated by BMI1. Here we report
that BMI1 induces miR-4436, which regulates cell proliferation and senescence in human cells. We also report
that miR-4436 targets a methyltransferase family member, HEMK1, which methylates glutamine residue in the
GGQ tri-peptide motif of human mitochondrial release factor (HMRF1L), and possibly other proteins.
Methods: To study the role of miR-4436 in regulating proliferation and senescence, we generated miR-4436
overexpressing MRC5 cells. We also overexpressed a miR-4436 inhibitor in MRC5 cells. Using these cells, we
performed cell proliferation and senescence assays to establish the role of miR-4436 in senescence. Next, we
performed 3’UTR reporter assays to define HEMK1 as bona fide target of miR-4436. The role of HEMK1 in
senescence and proliferation was also studied by proliferation and senescence assays, which include SA-β-gal
EdU uptake and H2AX foci formation assays, and Western blot analysis of various senescence-related proteins
such as p21, p53, p16 and pRB.
Results and Conclusions: Our data show that miR-4436 promotes cell proliferation and inhibits senescence in
human diploid fibroblasts. The miR-4436 inhibited HEMK1 expression and conversely, miR-4436 inhibitor
upregulated HEMK1 expression. We further show that miR-4436 posttranscriptionally downregulated HEMK1
expression via miR-4436 targeting sequences present in the 3’UTR of HEMK1 mRNA. Our results suggest that
miR-4436 may regulate proliferation and senescence by inhibiting expression of HEMK1. In summary our data
suggest that miR-4436 and its target HEMK1 are important for cellular senescence and pathological processes
that involve senescence such as aging. In addition, HEMK1 may be a candidate tumor suppressor. We are
further determining the mechanism of regulation of senescence by HEMK1, and examining the role of miR4436 and HEMK1 in breast cancer.
Inflammasome activation plays a detrimental role for host resistance against non-healing cutaneous
Leishmaniasis
Sang Hun Lee, Ph.D., NIAID/National Institute of Health
Infection with most L. major strains, such as L. major Friedlin (LmFn), can successfully be resolved in C57BL/6
mice. In contrast, the West African L. major Seidman strain (LmSd) causes a non-healing lesion and severe
35 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
pathology in the inoculated ear dermis by immune responses that remain to be elucidated. In comparison to
LmFn, infection with LmSd is associated with an early recruitment of CD4+ and CD8+ T cells, and especially
neutrophils to the site of inoculation. The pathology was also preceded by upregulated expression of multiple
cytokines and chemokines, including IL-17, CXCL1, IL-27, IL-10, and IL-1β, with secretion of IL-1β being
detected especially early. Whereas no phenotype was observed in IL-17 or CXCL-1 deficient mice, IL-1R
deficient mice, lacking the receptor for both IL-1α and IL-1β, as well as mice deficient in IL-1β, ASC and
caspase-1/11, showed minimal pathology and healed their infection with LmSd. The active form of caspase-1
could be detected in bone marrow derived macrophages infected with either L. major strain in vitro, and was
required for secretion of IL-1β by these infected cells. Altogether, these data suggest that early IL-1β secretion,
dependent on inflammasome assembly and caspase-1 activation, and induced far more strongly in vivo
following infection with the LmSd strain, plays a crucial role in the development of the severe pathology and
nonhealing response.
Development of long-acting urate oxidate by site-specific conjugation of fatty acid
Sung In Lim, University of Virginia
Hyperuricemia is an abnormally high level of uric acid in the blood, and caused by various factors including
diet, genetics, and metabolic disorder. In particular, it is one of the most feared complications, known as
tumor lysis syndrome (TLS), after treatment of leukemias and lymphomas. Precipitation of uric acid crystals in
kidney and joints may lead to acute renal failure and inflammatory arthritis, respectively. Urate oxidase (Uox)
is a therapeutic enzyme that catalyzes the degradation of uric acid into a water-soluble 5-hydroxyisourate. A
recombinant version of Uox, marketed as Rasburicase, was approved in 2009 by FDA for use as a treatment
and prevention of renal failure associated with TLS. However, its short in vivo half-life (8 h) leads to frequent
injections and patient’s noncompliance.
Albumin binding is an emerging strategy to prolong in vivo half-life of therapeutic proteins. Human serum
albumin (HSA) which is abundant in the blood has the longest half-life of three weeks, and transports fatty
acids to the liver through multiple binding sites. We investigated if Uoxwould obtain HSA-binding affinity
through fatty acid-conjugation, andsurvive longer in vivo. To ensure high homogeneity and the native
enzymatic activity upon fattyacid-conjugation, we implemented a combined use of non-natural amino acid
incorporation andclick chemistry to site-specifically attach a palmitic acid to a predetermined position of Uox.
Aphenylalanine analog, p-azido-L-phenylalanine, was genetically installed in substitution forW161 by an
orthogonal pair of amber suppressor tRNA/tRNA synthetase, and then grafted to anazido-palmitic acid via a
bifunctional PEG spacer using copper-free alkyne-azide cycloaddition.
The conjugate (Uox-Pal) was found to be chemically well-defined and maintain the nativeactivity of Uox. The
HSA-binding capability of Uox-Pal was evaluated in vitro throughimmobilization onto a HSA-coated support
followed by urate degradation assay.Pharmacokinetic behavior of Uox-Pal in comparison to Uox will be
studied in mice.
36 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
Role of NF-κB in the Function of Regulatory T Cells
Hyunju Oh, Ph.D., Columbia University
The immune system is crucial in providing protection against pathogens, but when maintenance of immune
homeostasis is perturbed, responses against self antigens may cause various autoimmune diseases. FoxP3+
regulatory T cells (Treg cells) have been extensively studied as a key regulator of self-tolerance, yet the
mechanism of their development and function remains unclear. Our lab has previously shown that the
transcription factor, NF-κB plays a role in the thymic development of natural Treg cells. In our study, c-Rel, a
member of the NF-κB transcription factor family, was shown to directly bind to an enhancer region of the
FoxP3 promoter upon TCR engagement and induce expression of FoxP3 mRNA. Another study from our lab
also suggested that PDK1 activation might be important in the suppressive function of Treg cells. Mice with
specific deletion of PDK1 in CD4+ T cells developed spontaneous colitis and Treg cells in those mice were
deficient in IL-10 production. We concluded that NF-κB activation upon TCR/CD28 engagement requires PDK1
since CD4+ T cells deficient in PDK1 could not induce NF-κB activation. These findings imply a possible role of
NF-κB in the signaling pathway governing the function of Treg cells. To further explore the role of NF-κB
specifically in Treg cells, we created various mouse strains with Treg-specific ablation of Pdk1, p65, c-Rel or
both p65 and c-Rel. Complete ablation of the canonical NF-κB pathway in Treg cells led to systemic
autoimmune diseases including psoriasis, lung inflammation and colitis, and early mortality of mice. Gene
expression profile analyses indicated that depletion of p65 or c-Rel changed expression of distinct sets of
genes. Our results strongly suggest that NF-κB has an important role in Treg function and that different NF-κB
subunits have differential roles in the thymus and periphery. This study will also shed light on how NF-κB
signaling regulates gene expression differentially in effector T cells and regulatory T cells.
Site-Specifically Labeled Ghrelin Receptor via Genetically-Encoded Unnatural Amin Acid
Minyoung Park, Ph.D., The Rockefeller University
The ghrelin receptor (GhR), a class A G protein-coupled receptor (GPCR) is mainly known as a key player in
regulating appetite, food intake, and thus maintaining energy homeostasis in body. Because balance in energy
uptake and expenditure is tightly controlled by various hormonal and endocrine systems, even slight
imbalance in this complex and diverse system can cause severe metabolic disorders like diabetes and obesity,
and/or obesity-associated diseases. Therefore the interaction between GhR and its endogenous peptide
ligand, ghrelin, has been intensively investigated as a promising drug target for treating obesity and other
metabolic disorders. However, there is no available marketed therapeutics for obesity and obesity-related
disorders, presumably due to the lack of understanding in GhR at its molecular level. We therefore decided to
develop a tool to analyze the interactions among components comprising the GhR signalosome (e.g., GhR,
ligands, G proteins, etc.), thereby leading to better understanding dynamic GhR signaling events. In our
present study, constitutively active GhR with its various ligands serves as a model displaying differential
conformations upon ligand stimulation, which lead to biased signaling pathways. Using unnatural amino acid
mutagenesis (UAAM), a UAA of choice, p-azido-L-phenylalanine (azF), was incorporated site-specifically into
GhR expressed in mammalian cell and the functionality of each GhR variant was accessed. Subsequently we
fluorescently labeled selected functional azF-GhR variant via strain-promoted alkyne-azide cycloaddition and
37 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
further confirmed that these labeled receptors remained functionally active in detergents by using a FRETbased assay. Complementing emerging information from static crystal structures of heavily modified GPCRs,
our labeling strategy will provide a straightforward way of uniformly labeling target GPCRs at specific sites
suitable for single molecule fluorescence studies to monitor dynamic conformational changes of GhR with
minimal perturbation. With facile applicability to other GPCRs and effector proteins, this type of labeling
approach can be used to spatially dissect signaling pathways of GhR, ultimately allowing us to design finetuned drugs for treating “diabesity” syndromes.
Behavioral Deficits in Nrf2 v. C57L/6J Mice After Early Postnatal Exposure to VPA
Hyun Chung Kim, Rutgers University
Autism is a dynamic neurodevelopmental syndrome resulting in dysfunctional behaviors. Valproic acid (VPA) is
clinically used as an anticonvulsant agent, and prenatal exposures to VPA has been linked to autism in humans
and animal models. The VPA-induced regression, or the disappearance of maturing developmental behaviors,
is thought to be caused by oxidative stress. To further evaluate the similarities between VPA treated mice and
autism, wild type C57BL/6J mice were treated with VPA and evaluated in a series of behavioral assays. Pups
were randomly assigned to a treatment group that received either a 400 mg/kg subcutaneous VPA injection or
a control group that received a saline injection on postnatal day 14. After measuring weight, a series of
developmental behavioral assays including hanging wire grip strength, negative geotaxis, Morris water maze,
rotorod, and locomotor activity test were used to examine differences in somatosensory reflex, motoric
responses, coordination, strength, and balance of juvenile mice. The VPA treated mice weighed significantly
less than the controls following injection. The treated mice performed the hanging wire test, mid air righting,
rotorod, and Morris water maze worse than the control mice. Overall, treatment with VPA on postnatal day 14
resulted in differences in various behavioral assays and provides further evidence linking early postnatal VPA
exposure and autistic regression.
38 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
KSEA NRC PAST KEYNOTE SPEAKERS
2013 S. Chan Choi, Ph.D., Professor, School of Business, Rutgers University
2012 Jeong-Sun Seo, M.D. Ph.D., Professor, College of Medicine, Seoul National University
2011 Choong-Seok Chang, Ph.D., Principal Physicist, Plasma Physics Laboratory, Princeton University
39 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
KASBP 2014 SPRING SYMPOSIUM AWARDEES
KASBP-Hanmi Fellowship Awardees:
2014 Dr. Chae, Young Chan (Wistar Institute), Dr. Cho, Min-Kyu (New York University)
Dr. Kim, Lark Kyun (Yale University), Dr. Kim, Yu Shin (Johns Hopkins Univeristy)
KASBP-Yuhan Fellowship Awardees:
2014 Dr. Kwon, Seouk Joon (Rensselaer Polytech Institute), Dr. Song, Jeongmin (Yale University)
Dr. Yang, Jae-Hyun (Harvard Medical School), Dr. Yang, Wan Seok (Columbia University)
KASBP-KSEA Fellowship Awardee:
2014 Dr. Jin, Keun-woo (Temple University)
KASBP PAST AWARDEES
KASBP-DAEWOONG ACHIEVEMENT AWARD
2009 김정은 Gilead Sciences, Inc. (Kainos .Medicine Inc, Korea, Current)
2010 주중광 University of Georgia
2011 김성호 University of California, Berkeley
2012 Dennis Choi Stony Brook Medicine and Stony Brook University
2013 Joseph Kim. Inovio Pharmaceutcals
KASBP-DAEWOONG AWARD
2006
배진건 Schering-Plough (Handok Pharmaceuticals, Korea, Current)
2007
박영환 Merck (National Cancer Center, Korea, Current)
2008
문영춘 PTC Therapeutics
2009
김홍용 Novartis
40 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
KASBP-DAEWOONG FELLOWSHIP
2006 김 한 Princeton University, 민재기 New York University,박혜진 Rutgers University
2007 문지숙 Harvard University, 박성연 Rutgers University, 이석근 Columbia University
2008 김정환 Rutgers University, 강민식 Columbia University, 이흥규 Yale University
2009 김덕호 Johns Hopkins University, 박진아 Harvard University, 최재민 Yale University
2010 기정민 Rockefeller University 김형욱 NIH, 안세진 Harvard University
2011 장환종 Boston College, 한무리 University of California, LA,
2012 장정호 (Dr. Chang, Jeong Ho) Columbia University
최재우 (Dr. Choi, Jaewoo) Oregon State University
2013 박은찬 (Dr. Eun Chan Park) Rutgers
이장은 (Dr. JangEun Lee) University of Pennsylvania
KASBP-HANMI FELLOWSHIP
2011 안형진 Rockefeller University, 조창훈 Abramson Research Center
2012 김유나 University of North Carolina, 이인혜 NIH, 태현섭 Yale University
2013 이주희 Dr. Ju-Hee Lee (Memorial Sloan-Kettering Cancer Center),
이경륜 Dr. Kyeong-Ryoon Lee (Rutgers University), 이만률 Dr. Man Ryul Lee (Indiana University)
KASBP-YUHAN FELLOWSHIP
2011 김기영 Boston University, 심중섭 Johns Hopkins University
2012 방숙희 University of Pennsylvania, 백정호 Columbia University, 허예민 University of Michigan,
2013 Dr. Dong Jun Lee (University of Chicago), Dr. Ingyu . Kim (Yale University),
Dr. Ja Yil Lee (Columbia University)
KASBP-GREEN CROSS FELLOWSHIP
2011 강성웅 Johns Hopkins University, 김미연 Columbia University,
소재영 Rutgers University, 조한상 Harvard Medical School, 황성용 NIEHS/NIH
2012 강효정 Yale University, 이용재 Yale University, 이정현 Columbia University,
윤재현 NIH, 조원진 Drexel University
2013 이윤정 (Dr. Yunjong Lee) Johns Hopkins University, 김준대 (Dr. Jun-Dae Kim) Yale University,
김배훈 (Dr. Bae-Hoon Kim) Yale University, 김자영 (Dr. Ja Young Kim-Muller) Columbia University
41 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
KASBP-SK LIFE SCIENCE FELLOWSHIP:
2013 Dr. Suk-Joon Hyung (Pfizer)
KASBP FELLOWSHIP
2009 최상호 NIH
2010 김상령 Columbia University, 윤태숙 Rutgers University, 허은미 Cal. Tech.
KASBP-KSEA FELLOWSHIP
2013 Mr. Sung In Lim, University of Virginia
KASBP-KUSCO FELLOWSHIP
2008 김현호 National Institutes of Health, 온택범 Harvard Medical School, 주원아 Wistar Institute
KASBP-KRICT FELLOWSHIP
2009 신승식 Rutgers University, 정은주 Columbia University, 백규원 University of Pennsylvania
KASBP-KHIDI FELLOWSHIP
2010
42 | P a g e
2014 KSEA Northeast Regional Conference / 2014 KASBP Spring Symposium
NOTE
43 | P a g e
SPONSORS
Make your life complete. Leading APIs and Global New Drugs